Clinical Trials Browser

INDUSTRY × Recurrence × liposomal doxorubicin × Clear all

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT00706953 2015-04-06

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Phase 2 Withdrawn

Multiple Myeloma, Recurrence